Virica Biotech Inc. announced it will collaborate with Oxford Biomedica plc to improve the yield and production efficiency of Oxford Biomedica's next generation lentiviral vector gene therapies using Virica's Viral Sensitizers (VSEs). Oxford Biomedica is a pioneer of cell and gene therapies. Its LentiVector® platform enables the successful development of breakthrough gene and cell-based medicines, and through collaborations with pharmaceutical partners, has delivered the first FDA and EMA approved CAR-T cell therapy.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
344.4 GBX | +1.31% |
|
+0.28% | +56.57% |
07-17 | Oxford Biomedica plc Announces Board Changes, Effective from September 2, 2024 | CI |
07-17 | Oxford Biomedica Names New Finance Chief | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.57% | 466M | |
+20.03% | 126B | |
+23.61% | 117B | |
+22.53% | 27.52B | |
-18.07% | 20.87B | |
-14.20% | 17.01B | |
-14.81% | 16.26B | |
+9.78% | 14.56B | |
-46.10% | 15.09B | |
+52.34% | 13.89B |
- Stock Market
- Equities
- OXB Stock
- News Oxford Biomedica plc
- Virica Biotech Announces R&D Partnership With Oxford Biomedica to Improve the Manufacturing of Lentiviral Vector Gene Therapies Using Viral Sensitizers